Alzheimers Res Ther (2014) 6:73
Generation 3: retatrutide, triple agonist GLP-1 + GIP + glucagon Retatrutide adds a third receptor, the glucagon receptor
Understanding the mechanism of drug action enables physicians to best pair it up with the appropriate patients
Tirzepatide results The SURMOUNT trials demonstrated average weight loss of 15 to 21 percent with tirzepatide over 72 weeks
16 Blood Thinner Dos and Donts Certain heart or blood vessel diseases Atrial fibrillation (abnormal heart rhythm) A heart valve replacement A risk of blood clots after surgery Congenital heart defects Anticoagulants make it harder for blood clots to form and include heparin, warfarin, dabigitran, apixaban, rivoroxaban, and edoxaban
The addition of a weight loss medication such as Ozempic, Wegovy, or Mounjaro will make losing that excess weight much easier for patients